Adagene spent fiscal 2025 proving it could do something its prior year made look impossible: generate revenue again. The Suzhou- and San Diego-based immuno-oncology company, whose contract revenue had collapsed to just $103,000 in fiscal 2024, recognized $7.7 million of collaboration revenue in fiscal 2025 - a roughly 74-fold swing off a near-zero base, with net loss narrowing by nearly half to $17.6 million. The poster child is muzastotug (ADG126), a masked, fully-human anti-CTLA-4 antibody whose Phase 1b/2 data in late-line microsatellite-stable colorectal cancer have drawn two Big Pharma combination partners, an FDA Fast Track designation, and a year of sharply improved financial discipline.
The quarter that matters most this report, though, is not a quarter at all; it is the balance sheet. Adagene raised about $70 million in an April 2026 public offering of 18.7 million ADSs priced at $3.75, lifting cash from $74.5 million at year-end 2025 to a preliminary $127.9 million on June 30, 2026. That roughly doubling of the cash buffer converts a cash-hungry clinical-stage burn into a runway the company says funds its operations into the back half of the decade - long enough to see whether muzastotug's data hold up in the pivotal-ish expansion cohorts that are the entire bull case.
The stock has already repriced for much of this. ADAG closed August 11, 2026 at $3.89, up about 79% over fifty-two weeks and near the top of a $1.30-to-$4.85 range, a $257 million market cap against roughly $128 million of cash and no material debt. The valuation question is no longer whether the company can survive; it is whether muzastotug's 29-to-31 percent response rates in a notoriously hard-to-treat cancer, and the Incyte and Sanofi collaborations built around them, justify a clinical-stage one-asset story trading at a premium to its own cash-adjusted peers. The next earnings release, scheduled for August 12, 2026, begins the counting.